Development of Effective Tumor Vaccine Strategies Based on Immune Response Cascade Reactions

Adv Healthc Mater. 2021 Jul;10(13):e2100299. doi: 10.1002/adhm.202100299. Epub 2021 May 22.

Abstract

To solve the problems of high toxicity and poor efficacy of existing tumor treatment methods, researchers have developed a variety of tumor immunotherapies. Among them, tumor vaccines activate antigen-presenting cells and T lymphocytes upstream of the cancer-immunity cycle are considered the most promising therapy to activate the immune system. Nanocarriers are considered the most promising tumor vaccine delivery vehicles, including polymer nanocarriers, lipid nanocarriers, inorganic nanocarriers, and biomimetic nanocarriers that have been developed for vaccine delivery. Based on the cascade reaction for tumor vaccines to exert their effects, this review summarizes the four key factors for the design and construction of nano-tumor vaccines. The composition and functional characteristics of the corresponding preferred nanocarriers are illustrated to provide a reference for the development of effective tumor vaccines. Finally, potential challenges and perspectives are illustrated in the hope of improving the efficacy of tumor vaccine immunotherapy and accelerating the clinical transformation of next-generation tumor vaccines.

Keywords: cross-presentation; immunotherapies; nanocarriers; smart response; tumor vaccines.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Cancer Vaccines*
  • Drug Delivery Systems
  • Humans
  • Immunity
  • Immunotherapy
  • Neoplasms* / therapy

Substances

  • Cancer Vaccines